Metsera alum joins Structure as COO Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 17 April, 2026

ASCO is about to deliver some make-or-break cancer data. Join us to figure out which pipeline bets will pay off. Get your spot now.

presented by CNS-3D Brain Organoids Pre­dict Clin­i­cal Seizure Li­a­bil­i­ty, New Study Da­ta

news Kailera raises $625M IPO in biotech record Lilly’s tirzepatide sheds lean muscle harder than Novo’s semaglutide, study suggests Peer Review Novartis' Vas Narasimhan heads to Anthropic's board; Metsera alum joins Structure as COO

Apr 28 12:30 pm ET Connection ≠ continuity: Rethinking long-term evidence in the age of tokenization sponsored by PicnicHealth Apr 29 12:00 pm ET From genotype to outcomes: Real-world evidence in glomerular diseases sponsored by Natera May 05 11:00 am ET The path to self-driving: Leveraging agentic AI to drive the future of clinical drug development sponsored by Medable May 12 10:30 am ET Rules of engagement: How G3BP2 paves the way to rationalize novel degrons sponsored by Thermo Fisher

The R&D 15 is John Carroll’s annual reckoning with where biopharma’s biggest players are really investing — and where they’re not. This year he’s back at the table with some of the industry’s top research chiefs for a frank, one-hour conversation on the trends shaping drug development in 2026 and beyond. Join us.

ENDPOINTS PHARMA RFK Jr. defends FDA, Makary following Republican questions OpenAI debuts a life sciences AI model, entering crowd of tech giants selling to pharma Using versus selling lucrative PRVs: Moderna's cautionary tale

in case you missed it 1. Cochrane review dismissing amyloid drugs draws immediate backlash 2. Roche to start a new Phase 3 trial for Elevidys after getting rebuffed by EU regulator last year 3. News Briefing MeiraGTx buys back gene therapy from J&J; Storm brings in $56M Series C; Adlai Nortye nabs $150M 4. Lilly's obesity pill heads for diabetes filing after heart risk trial 5. Women’s health biotech Freya Biosciences advances microbial therapy for IVF implantation failure 6. Novo Nordisk has hired 2,000 this year to reshape workforce 7. FDA's accelerated approval for drugs needs more transparency, says research firm